Making your Petition

Any person may petition the Minnesota Department of Health ("the department" or "MDH") to add an approved delivery method to those listed in subdivision 14 of Minnesota Statutes section 152.22.

Petitions will be accepted only between June 1 and July 31, 2017. Petitions received outside of these dates will not be reviewed.

Petitions must be sent by certified U.S. mail to:

Minnesota Department of Health
Office of Medical Cannabis
P.O. Box 64882
St. Paul, MN 55164-0882

You must mail the original copy of the petition with an original signature.

Complete each section of this petition and attach all supporting documents. Clearly indicate which section of the petition an attachment is for.

If you are petitioning for the addition of a delivery method that was considered but not approved in a prior year's petition process, you must include new scientific evidence or research to support your petition or describe substantially different therapeutic benefits. Please refer to our website to see which delivery methods were reviewed in prior years (http://www.health.state.mn.us/topics/cannabis/rulemaking/adddelivery.html).

Each petition is limited to ONE proposed delivery method. If you want to request more than one delivery method be added, you must submit multiple petitions.

If a petition does not meet the standards for submission, it will be dismissed without being considered.

Petition review process

If the petition is accepted for consideration, MDH will post notice of review of the petition on its medical cannabis website and allow public comment and input on the petition for at least 30 days. MDH staff will also provide information about the proposed delivery method and a review of the current literature regarding its effectiveness.

The Commissioner will approve or deny the petition by December 1 of the year the petition is accepted for consideration.

You may withdraw your petition any time before it is posted on the website for public comment by submitting a written statement to the Department stating that you wish to withdraw it.
Minnesota Medical Cannabis Program
Petition to Add an Approved Delivery Method

To obtain this information in a different format, call:
(651) 201-5598 in the Metro area and (844) 879-3381 in the Non-metro.
Minnesota Medical Cannabis Program  
Petition to Add an Approved Delivery Method

**Section A: Petitioner's Information**

| Name (First, Middle, Last): |  
| Home Address (including Apartment or Suite #): |  
| City: | State: | Zip Code: |

**Section B: Delivery Method You Are Requesting Be Added**

Please specify and provide a brief description of the proposed delivery method. Be as precise as possible in describing the delivery method you are requesting be added. Attach additional pages as needed.

Inhalational - see 4 references attached. Pubmed.com  
Nasal Administration, while new to medical cannabis, is used with common intranasal steroid applications.  
A simple adapter to the typical vape pen mouth piece would do fine, but I bet the boys at the labs can come up with something fancier ($$$).  
Good luck.  
(not Lorax, though I do speak  
for the medical truths)
Section C: Anticipated Benefits from the Proposed Delivery Method

Describe the anticipated benefits from the proposed delivery method and why it is better than currently approved delivery methods. Identify patient populations that do not benefit from current delivery methods.

Attach additional pages if needed.

Vaping is the most palatable method and works for many, some can’t, will not use it and sublingual/oral methods are too unreliable.

stops stigma of smoking which certain patients will always equate with pot.
Section E (optional): Scientific Evidence of Support for the Delivery Method

It will strengthen your petition to include evidence generally accepted by the medical community and other experts that addresses the effectiveness of the proposed medical cannabis delivery method and discusses its potential risks and benefits. This includes but is not limited to full text, peer-reviewed published journals or other completed medical studies. Please attach complete copies of any article or reference, not abstracts.

I have attached relevant articles. (check box if you have attached scientific articles or studies)

Section F (optional): Letters in Support

Attach letters of support from persons knowledgeable about the use of the delivery method with medical cannabis.

I have attached letters of support. (check box if you have attached letters of support)

Section I: Acknowledgement and Signature

Please Note: Any individually identifiable health information relating to any past, present, or future health condition or health care contained in this petition is classified as a health record under Minnesota Statutes §144.291, and is not subject to public disclosure.

I certify that the information provided in this petition is true and accurate to the best of my knowledge.

DATE (mm/dd/yyyy)
Efficacy of the novel nasal steroid S0597 tested in an environmental exposure unit.

Long-term administration of a Niemann-Pick C1-like 1 inhibitor, ezetimibe, does not worsen bile lithogenicity in dyslipidemic patients with hepatobiliary diseases.

Antibody/doxycycline combined therapy for pulmonary ricinosis:
3. Attenuation of inflammation improves survival of ricin-intoxicated mice.
4. **Early phase resolution of mucosal eosinophilic inflammation in allergic rhinitis.**


5. **Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study.**


6. **Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study.**


7. **The enhancing effect of nasal absorption of FITC-dextran 4,400 by beta-sitosterol beta-D-glucoside in rabbits.**


8. **Ecbalium elaterium (squirtling cucumber)--remedy or poison?**

Maitani Y, Nakamura K, Suenaga H, Kamata K, Takayama K, Nagai T.
PMID: 10845682

10. The relationship between the rigidity of the liposomal membrane and the absorption of insulin after nasal administration of liposomes modified with an enhancer containing insulin in rabbits.
Muramatsu K, Maitani Y, Takayama K, Nagai T.
PMID: 10529890

11. Effect of topical fluticasone propionate on the mucosal allergic response induced by ragweed allergen and diesel exhaust particle challenge.
Diaz-Sanchez D, Tsien A, Fleming J, Saxon A.
PMID: 10075860

12. High absorbency and subchronic morphologic effects on the nasal epithelium of a nasal insulin powder dosage form with a soybean-derived sterylglucoside mixture in rabbits.
PMID: 9743259

Ando T, Maitani Y, Yamamoto T, Takayama K, Nagai T.
PMID: 9743258

14. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the...
treatment of seasonal allergic rhinoconjunctivitis.
Juniper EF, Kline PA, Ramsdale EH, Hargreave FE.
PMID: 2107241

Back to top